Premiere pneumococcal conference will showcase PATH's work

March 9, 2010 by PATH

PATH participation will help bring efforts to develop new pneumococcal vaccines for low-resource countries into focus

Top researchers and clinicians from around the world will come together for the Seventh International Symposium on Pneumococci and Pneumococcal Diseases from March 14 to 18, 2010, in Tel Aviv, Israel. PATH is pleased to be a co-sponsor as leading scientists convene to review the latest highlights and scientific achievements within the pneumococcal field, including topics related to epidemiology, vaccines, and treatment.

Dr. Mark Alderson, director of PATH’s pneumococcal vaccine development project, will give an overview of PATH’s activities to advance the development of new pneumococcal vaccines for children in the developing world. Several of PATH’s partners on the project will also have an opportunity to share new developments in their collaborative work with PATH.

Visit PATH at our booth in the exhibition hall to learn more about our work. Several additional scientific, administrative, and communications staff members from PATH’s pneumococcal vaccine project will also attend the symposium.

About pneumococcal disease

Each year, nearly one million children die from pneumococcal disease, mostly in the developing world. The pneumococcus bacterium is the most common cause of severe pneumonia, which kills more children before their fifth birthdays annually than any other disease worldwide. Pneumococcus also causes sepsis (blood infection) and meningitis (brain infection), which kill and disable children around the globe, and is a leading cause of bacterial otitis media (middle ear infection).

More information